- AC Immune (NASDAQ:ACIU -0.4%) announces that it plans to initiate a first in-human study of its investigational PET imaging agent for Parkinson's disease (PD). The company says the agent is highly selective for alpha-synuclein aggregates, an established drug target for the disorder. The tracer will enable PD drug developers to monitor the efficacy of PD therapies.
- The company has been collaborating with Biogen (BIIB +0.3%) on the program for almost two years on a non-exclusive basis.
- Shares were up over 5% before retracing.